ESCCA workshop on Minimal/Measurable Residual Disease in CLL

2nd ESCCA Meeting –
July 6, 2018 –
Valencia, Spain


  • Detection of minimal residual disease (MRD) in leukaemia is becoming
    increasingly important as treatments improve.
  • In chronic lymphocytic leukemia (CLL) the level of minimal residual disease
    (MRD) after therapy is an independent predictor of outcome. Given the
    large number of new agents being explored for CLL therapy, using MRD as a
    trial endpoint could greatly reduce the time necessary to identify the most
    effective treatment approach. In addition to response assessment, MRD
    analysis may also be used to guide treatment duration.
  • In this training course the clinical, biological and regulatory aspects of MRD
    analysis will be discussed. Participants will gain understanding of the
    analytical approach to MRD detection with interactive sessions plus
    assisted data analysis and interpretation of real cases under the guidance
    of an expert hematologist.


  • This Workshop is part of the ESCCA Program for Continuous Education in
    Cytometry (ECEC). ECEC integrates educational and training initiatives
    oriented to provide new skills and tools to design, optimize and manage
    cytometric analyses and interpret the results obtained.
  • The ESCCA International Summer School on Cytometry consists of a series
    of parallel 5-day courses limited to 20 students per course.
  • ESCCA has established the European Certification in Cytometry.
  • Examination for this Certificate can be taken in national and international
    ESCCA events.
  • For more information on ESCCA Educative initiatives visit